Aims Elevated plasma levels of proinflammatory cytokines have been reported in patients with congestive heart failure. The purpose of this study was to assess whether cytokines improve risk stratification in a homogenous group of NYHA class III patients with a left ventricular ejection fraction <40%.
Introduction
The prevalence and incidence of congestive heart failure are still increasing in the western world [1, 2] . Although the introduction of ACE inhibitors, and more recently betablockers, has improved prognosis, 1-year mortality of patients with severe heart failure is still as high as 35% [3] [4] [5] . For patients with advanced heart failure, cardiac transplantation remains an alternative option. Unfortunately, organ supply is limited and average waiting periods are currently reported to be in the range of 12 to 15 months [6] . Therefore, the decision to proceed to transplantation has to be made quite early before the patients are in irreversible end-stage heart failure. Consequently, most patients who present for the evaluation of cardiac transplantation are currently in NYHA functional class III [6] . The decision to proceed to cardiac transplantation is primarily based on -besides NYHA functional class -left ventricular ejection fraction and peak oxygen uptake (peak VO 2 ) [7] . However, risk stratification has to be further optimized as up to 25% of the patients on the waiting list die before transplantation and up to 20% are removed from the waiting list due to marked clinical improvement [6, 8] . Several other parameters, such as plasma norepinephrine, natriuretic peptides and big endothelin have been shown to correlate with NYHA class and prognosis [9] [10] [11] . The prognostic value of these parameters in clinical decisionmaking for cardiac transplantation, however, is uncertain, as the majority of previous studies included patients from all NYHA functional classes.
During the past few years, cytokines have gained increasing attention in cardiovascular disease [12] [13] [14] [15] [16] [17] . In patients with advanced heart failure, tumour necrosis factor alpha was the first cytokine reported to be elevated [18] [19] [20] [21] [22] . In addition, other cytokines such as interleukins -1, -6, -10, and the soluble form of the leukocyte surface marker CD14 (sCD14) have been shown to correlate with the clinical severity of left ventricular dysfunction [23] [24] [25] [26] [27] [28] . The aim of the present study was to prospectively examine whether cytokines are independent prognostic parameters in NYHA functional class III patients. If this were the case, this would allow an improvement in risk stratification and thus identify potential candidates for cardiac transplant, in addition to established risk predictors. Furthermore, the circadian variability of potential prognostic cytokines was investigated in order to determine the ideal time for drawing blood.
Patients and methods

Study population
The study group included 91 congestive heart failure patients, all in NYHA functional class III, who were admitted to the Department of Cardiology at the University of Heidelberg from February 1996 to October 1997 for the evaluation of heart transplantation. Additional inclusion criteria were a left ventricular ejection fraction <40% and a diagnosis of either dilated cardiomyopathy or ischaemic heart disease, confirmed by cardiac catheterization. Patients with a serum creatinine >2 mg.dl 1 , implantable cardioverterdefibrillator, chronic inflammatory, neurological, orthopaedic, peripheral vascular and severe pulmonary diseases or malignancies were excluded. The study complies with the Declaration of Helsinki and was approved by the institutional ethics committee. Written informed consent was provided by all patients enrolled in the study. The clinical characteristics of the patient population are listed in Table 1 .
Biochemical analysis
For the determination of plasma concentrations of cytokines, big endothelin and norepinephrine, 5 ml of venous blood were drawn at noon from an antecubital vein (EDTA containing tubes, Sarstedt, Nü brecht, Germany) after at least 30 min of rest (supine position), centrifuged at 3000 rpm at 4 C for 10 min and the supernatant stored at 20 C.
Cytokines and big endothelin were measured with commercially available ELISA tests according to the recommendations of the respective supplier: Interleukin-1 (Biosource International, California, U.S.A.): minimal detectable concentration 10 pg.ml 1 , intra-assay precision 5·2-5·5%, inter-assay precision 8·5-11·0%, recovery 96-103%; interleukin-6 (R&D Systems, Minneapolis, U.S.A.): minimal detectable concentration 0·7 pg.ml 1 , intraassay precision 1·7-4·3%, inter-assay precision 3·3-6·3%, recovery 84-103%; Interleukin-10 (Pharmingen, Hamburg, Germany): minimal detectable concentration 4 pg.ml 1 , intraassay precision 8·0-14·5%, inter-assay precision 15·2-19·8%, recovery 82-115%; Interleukin-12 (R&D Systems, Minneapolis, U.S.A.): minimal detectable concentration 0·5 pg.ml 1 , intra-assay precision 2·5-4·9%, inter-assay precision 7·6-15·0%, recovery 83-117%; tumour necrosis factor alpha (R&D Systems, Minneapolis, U.S.A.): minimal detectable concentration 0·18 pg.ml 1 , intra-assay precision 8·7-14·3%, inter-assay precision 16·1-22·6%, recovery 86-105%; sCD14 (IBL, Hamburg, Germany): minimal detectable concentration 1 ng.ml 1 , intra-assay precision 5·2-5·5%, inter-assay precision 7·4-7·6%, recovery 92-109%; GM-CSF (Biosource International, California, U.S.A.): minimal detectable concentration 1 pg.ml 1 , intra-assay precision 4·9-6·7%, inter-assay precision 6·9-8·1%, recovery 83%; Big endothelin (Biomedica, Vienna, Austria): minimal detectable concentration 0·05 fmol.ml 1 , intra-assay precision 3·9-4·9%, inter-assay precision 6·1-6·9%, recovery 94-103%. The plasma concentrations of norepinephrine were quantified by radioenzymatic assay [29] and those of C-reactive protein (Dade Behring, Marburg, Germany) by nephelometry [30] . 
Circadian variability
Within a 24-h period (0800 h to 0800 h) venous blood samples were obtained consecutively every 4 to 8 h from 24 out of 91 patients, and plasma levels of interleukin-6, tumour necrosis factor alpha, big endothelin and C-reactive protein were determined by ELISA or nephelometry, respectively, as described above.
Radionuclide ventriculography
For determination of left ventricular ejection fraction, an equilibrium rest radionuclide ventriculogram was performed with a multicrystal gamma camera (Orbiter, Siemens, Erlangen-Nü rnberg, Germany) in the left anterior oblique view, as previously described [31] . Briefly, red blood cells were labelled with 2 ml of stannous pyrophosphate and 30 mCi of 99m Tc (Dupont, Bad Homburg, Germany) were applied. End-systolic and end-diastolic activity over the left ventricle were measured by ECG-triggered data acquisition. Left ventricular ejection fraction was calculated according to the formula: (end-diastolic end-systolic counts)/ end-diastolic counts.
Peak oxygen consumption
Peak VO 2 was defined as the highest oxygen consumption measured during the last 30 s of symptom-limited bicycle exercise testing. The testing protocol consisted of 15 W increments every 2 min. Oxygen uptake and carbon dioxide production were measured with a respiratory gas analyser on a breath-by-breath basis (Oxycon alpha, Jaeger, Wü rzburg, Germany).
Clinical follow-up
Patients were routinely seen in the outpatient clinic at the Department of Cardiology at the University of Heidelberg. Medical therapy was adjusted as needed. Follow-up information was available for all patients at a pre-established time point (1 August 1999) . Information about circumstances of death was obtained from hospital medical records or referring physicians. Mean follow-up was 22 (13) months (range 1 to 41 months).
The pre-defined study end-point was cardiac death, i.e. sudden death or death due to irreversible heart failure. For analysis, patients were divided into two groups, depending on whether they were still alive (i.e. survivors) or whether they had died from cardiac causes (i.e. non-survivors) at the end of the follow-up period (1 August 1999). For patients who obtained a heart transplantation the follow-up period ended with the date of transplantation.
Statistical analysis
The data are presented as mean (SD). To test for significant differences between the study groups the Wilcoxon test was used and a value of P<0·05 was considered indicative of a statistically significant difference. Pearson's correlation coefficient indicated the association between variables. Differences in event-free survival were detected by the Kaplan-Meier product The values are expressed as mean (SD); ns=not significant. LVEF=left ventricular ejection fraction; IL-6/-1/-10/-12=interleukins -6 -1 -10 -12; TNF-= tumour necrosis factor alpha.
limit method and compared by the Petro-Prentice generalized log-rank test [32, 33] . To identify the most important predictors for cardiac death, multivariate Cox proportional hazards analysis and subsequent bestsubset selection process were used to build up a ranking score for variables in a multivariate model for risk stratification [34, 35] .
The ability of each model to predict survival was assessed by calculating the area under the curve. The area under the curves for different models were compared by the area test for correlated test results [36] . The maximum likelihood estimated binormal receiveroperating curves were constructed by means of plotting true-positive rates (sensitivity) against false-positive rates (1/specifity) [37] . Additionally, the results were confirmed (data not shown) by recalculating the area under the curve comparison applying a non-parametric approach [38] .
Results
During the follow-up period of 22 (13) months, 31 patients (34%) died, all of them from cardiovascular causes (20 sudden death, 11 irreversible pump failure). As summarized in Table 2 , there were no significant differences between survivors and non-survivors in patient age, gender, heart rate, blood pressure and cause of heart failure. However, significant differences for left ventricular ejection fraction and peak VO 2 were noticed. Among the cytokines only interleukin-6 proved to be statistically significant between the two groups, with the mean plasma concentrations being more than twice as high in non-survivors as in survivors. Plasma concentrations of norepinephrine, big endothelin, interleukins -1, -10, -12, tumour necrosis factor alpha, GM-CSF and sCD14 showed a very heterogeneous distribution within this homogeneous group of NYHA functional class III patients. However, there was no significant difference between survivors and non-survivors, indicating a lack of prognostic relevance in this selected subgroup of congestive heart failure patients.
The plasma concentration of interleukin-6 was only weakly correlated with peakVO 2 (r=0·45), norepinephrine (r=0·21), big endothelin (r=0·24), tumour necrosis factor alpha (r=0·35) and interleukin-12 (r=0·21). No significant relationship was observed between interleukin-6 and either left ventricular ejection fraction or any of the other cytokines.
Univariate analysis
Chi-squared values of cytokines, left ventricular ejection fraction and peak VO 2 ranged from 0·06 (sCD14, minimum, ns) to 13·36 (peak VO 2 , maximum, P=0·0003) with big endothelin: 0·43, ns; interleukin-10: 0·59, ns; tumour necrosis factor alpha: 0·67, ns; interleukin-1: 1·49, ns; GM-CSF: 1·60, ns; left ventricular ejection fraction: 8·52, P=0·0035; interleukin-6: 8·95, P=0·028 in between.
The prognostic significance of interleukin-6 as well as left ventricular ejection fraction and peak VO 2 is also further corroborated by Kaplan-Meier analysis (Fig. 1) .
To discriminate between prediction of short-term (up to 6 months) and long-term (d1 year) survival, the data were analysed in more detail, as shown in Table 3 . There was no significant difference in interleukin-6, left ventricular ejection fraction and peak VO 2 between survivors and non-survivors at 3 and 6 months. A significant difference between both groups could only be noticed after 1 year of follow-up. The most likely explanation for a lack of prognostic significance of both left ventricular ejection fraction and peak VO 2 during the first 6 months of follow-up is the relatively small number of end-points, as the mean values of both parameters and thus the difference between non-survivors and survivors remained relatively stable during the entire follow-up period. Therefore the prognostic significance of interleukin-6 depends on the duration of the 
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follow-up period, whereas left ventricular ejection fraction and peak VO 2 appear to allow for a prediction of both short-and long-term survival.
Multivariate analysis
Multivariate logistic regression analysis revealed not only an independent predictive value of left ventricular ejection fraction and peak VO 2 , but also of the interleukin-6 plasma concentrations. Table 4 indicates that interleukin-6, as a single parameter, is at least as predictive as left ventricular ejection fraction. The predictive value was further improved by the combination of left ventricular ejection fraction with either interleukin-6 or peak VO 2 . The combination of the three variables left ventricular ejection fraction, peak VO 2 and interleukin-6 added little to the prognostic impact. This is also underlined by the receiver-operating curves analysis depicted in Fig. 2 , which shows area under the curves for every single parameter (left ventricular ejection fraction: 0·65; interleukin-6: 0·67; peak VO 2 : 0·72) and the combination of three parameters (area under the curve: 0·76).
Circadian variation
Concentrations of tumour necrosis factor alpha and C-reactive protein remained relatively stable (variation <10%) without any signs for a circadian rhythm, whereas the plasma levels of interleukin-6 rose continuously during the day with a peak at midnight (Fig. 3) . The plasma concentrations of big endothelin showed only small variations (<25%).
Discussion
This prospective study provides evidence that the plasma concentrations of interleukin-6 may be a clinically useful prognostic marker for long-term survival (d1 year) of NYHA functional class III patients. In contrast, the plasma concentrations of interleukins -1, -10 and -12, tumour necrosis factor alpha, GM-CSF, and sCD14 did not allow the identification of non-survivors. The plasma concentrations of interleukin-6 were shown to correlate with the severity of congestive heart failure and to predict prognosis [39, 40] . However, the significance of these findings for clinical decision making is limited, as the functional classes within those study populations ranged from NYHA functional class I to IV. Patients in NYHA functional classes I and II are generally not considered for heart transplantation and patients in NYHA functional class IV are known to have a very poor prognosis. Currently, most patients to be evaluated 23·57  <0·0001  LVEF plus peakVO 2  20·82  <0·0001  IL-6 plus LVEF  18·18  <0·0001  PeakVO 2  13·03  0·0001  IL-6  9·30  0·003  LVEF  9·15  0·012 For abbreviations, see Table 2 .
for heart transplantation present in NYHA functional class III. For this reason the finding that interleukin-6 allows discrimination between survivors and nonsurvivors may be of importance for risk stratification in a well-defined group of NYHA functional class III patients. However, according to the present study the prognostic power of interleukin-6 for decision-making regarding heart transplantation might be limited, as interleukin-6 failed to predict short-term (up to 6 months) survival.
Plasma levels of interleukins -1 and -10, tumour necrosis factor alpha, big endothelin and soluble CD14 were not significantly different between survivors and non-survivors. Although there are reports of significant correlations of all of these cytokines with NYHA functional class and a prognostic impact in populations with patients ranging from NYHA functional class I (or II) to IV [11, 12, 16, 18, [21] [22] [23] 26] , their prognostic power in the clinically important homogenous subgroup of NYHA functional class III patients appears to be limited. Tsutamoto et al. recently reported a higher proportion of females in the group of non-survivors, than in the group of survivors [39] . However, in the present study gender, age and mean heart rate were not different between the groups.
In addition, significant differences between survivors and non-survivors for the well-established prognostic indices peak VO 2 and left ventricular ejection fraction were observed [7, [41] [42] [43] . These two predictors ranked within the top three of the score list for the prognostic impact of single parameters (see Table 4 ). Multivariate logistic Cox regression analysis revealed that interleukin-6 has an predictive value independent of these two parameters. A combination of interleukin-6 plasma concentrations with either left ventricular ejection fraction alone or with left ventricular ejection fraction plus peak VO 2 further increased its predictive power. Most important is the contrast with left ventricular ejection fraction and peak VO 2 , whose assessment requires sophisticated equipment and, thus, adds to the costs of patient evaluation, since plasma concentrations of interleukin-6 may easily be determined at relatively low cost in every clinical routine laboratory.
At present, the pathophysiological link between interleukin-6 serum concentrations and the severity and prognosis of congestive heart failure is not well understood. Interleukin-6 is a pleiotropic cytokine that is mainly produced by leukocytes, but also by endothelial and vascular smooth muscle cells [44] [45] [46] . In contrast to tumour necrosis factor alpha, interleukin-6 concentrations have been shown to be directly related to cardiac filling pressures and inversely to cardiac output [27] . According to a recent study by Lommi et al., high systemic venous pressure is the single most 
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important predictor of elevated plasma concentrations of interleukin-6 [27] . However, whether the increase in plasma concentrations of interleukin-6 is due to excessive spillover from the heart or the peripheral vasculature is still not known. Finally, it remains to be determined whether interleukin-6 itself exerts a deleterious effect in the pathophysiology of heart failure, such as tumour necrosis factor alpha, or whether it is just a marker for poor outcome [47] . Recently, Hirota et al. reported that in mice with a cardiac specific knockout of the gp130 receptor, apoptotic cell death of cardiomyocytes is increased several-fold and survival markedly decreased after aortic banding compared with wild-type mice [48] . As the gp130 receptor is a ligand of cardiotrophin, a member of the interleukin-6 family, it may be concluded that cytokine-induced stimulation of the gp130 receptor exerts a protective, antiapoptotic effect that mitigates the transition from hypertrophy to heart failure. Thus, similar to natriuretic peptides, the rise in interleukin-6 plasma concentrations might translate into potentially beneficial and not detrimental effects.
The major limitation of routine determination of interleukin-6 is its low specificity, as the plasma concentrations of interleukin-6 are influenced by a variety of diseases such as inflammation and malignancies. However, none of the patients included in the present study suffered from a systemic infection or a neoplasm and the prognosis of the patients was entirely determined by their cardiac disease.
The circulating levels of interleukin-6 show a natural variability over the time-course of the disease [49] . It is important to realize that interleukin-6 levels follow a circadian rhythm with a sharp nocturnal rise [50] . In contrast to other potential predictors, such as tumour necrosis factor alpha or big endothelin, which showed no or only minor changes, interleukin-6 concentrations rose by up to 250% of the baseline level (at noon) in the present study. Even within 8 h a substantial rise in the interleukin-6 concentration was observed. To circumvent this problem, blood samples for interleukin-6 should always be withdrawn at the same time (at noon) as in the present study. Finally, the potential influences on interleukin-6 plasma concentrations of the many drugs used in congestive heart failure treatment need to be determined. Aspirin (300 mg per day) has recently been shown to lower cytokine concentrations by approximately 30% in patients with chronic stable angina [51] . ACE inhibitors seem to be able to lower cytokine levels in congestive heart failure and, in regard to the well-known interaction between the sympathoadrenergic and immune systems, beta-blockade may lower cytokine concentrations as well [52, 53] . In the present study, 100% of the patients (all survivors and non-survivors) received ACE inhibitors. Therefore the influence of ACE inhibitors on cytokine levels and survival could not be investigated. The number and proportion of patients receiving aspirin and/or a beta-blocking agent were too small to allow for firm conclusions in this respect. Although catecholamines are thought to stimulate interleukin-6 release [53] and there was a trend towards higher norepinephrine plasma levels in non-survivors, interleukin-6 and norepinephrine were only loosely correlated in the present study. Furthermore multivariate regression analysis previously revealed that both are independent risk factors [54] . In summary, the present study indicates that interleukin-6 is a strong predictor of long-term clinical outcome in a homogenous group of NYHA functional class III patients. As an independent predictor of prognosis, interleukin-6 may help to improve risk stratification in conjunction with peak VO 2 and left ventricular ejection fraction. However, in contrast to left ventricular ejection fraction, interleukin-6 does not allow the prediction of short-term (up to 6 months) survival, thus limiting its value regarding clinical decision making for cardiac transplantation.
